0001209191-23-004345.txt : 20230123
0001209191-23-004345.hdr.sgml : 20230123
20230123082705
ACCESSION NUMBER: 0001209191-23-004345
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230118
FILED AS OF DATE: 20230123
DATE AS OF CHANGE: 20230123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McNeill Jonathan
CENTRAL INDEX KEY: 0001824673
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 23542592
MAIL ADDRESS:
STREET 1: C/O DYNE THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-18
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001824673
McNeill Jonathan
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD
WALTHAM
MA
02451
0
1
0
0
See Remarks
Common Stock
2023-01-18
4
M
0
10000
0.73
A
77600
D
Common Stock
2023-01-18
4
S
0
10000
14.03
D
67600
D
Stock Option (right to buy)
0.73
2023-01-18
4
M
0
10000
0.00
D
2029-02-25
Common Stock
10000
68528
D
This is an inadvertent late filing due to an administrative error.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.
Senior Vice President of Business Development
/s/ Richard Scalzo, Attorney-in-Fact
2023-01-23